Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arvinas, Inc. stock logo
ARVN
Arvinas
$7.67
$9.29
$6.05
$14.51
$494.87M1.74699,291 shs957,444 shs
FibroGen, Inc stock logo
FGEN
FibroGen
$9.77
+8.3%
$9.21
$4.85
$12.60
$39.57M0.7740,794 shs31,125 shs
Hypermarcas stock logo
HYPMY
Hypermarcas
$3.81
$4.47
$3.71
$5.50
$2.68B0.723,548 shs9,555 shs
MorphoSys AG stock logo
MOR
MorphoSys
$18.96
$18.96
$4.18
$19.50
$2.86B1.21.02 million shsN/A
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arvinas, Inc. stock logo
ARVN
Arvinas
0.00%+8.18%-10.29%-29.89%+2.68%
FibroGen, Inc stock logo
FGEN
FibroGen
0.00%0.00%0.00%0.00%+89.34%
Hypermarcas stock logo
HYPMY
Hypermarcas
-6.71%-5.69%-13.80%-8.63%-22.95%
MorphoSys AG stock logo
MOR
MorphoSys
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arvinas, Inc. stock logo
ARVN
Arvinas
$7.67
$9.29
$6.05
$14.51
$494.87M1.74699,291 shs957,444 shs
FibroGen, Inc stock logo
FGEN
FibroGen
$9.77
+8.3%
$9.21
$4.85
$12.60
$39.57M0.7740,794 shs31,125 shs
Hypermarcas stock logo
HYPMY
Hypermarcas
$3.81
$4.47
$3.71
$5.50
$2.68B0.723,548 shs9,555 shs
MorphoSys AG stock logo
MOR
MorphoSys
$18.96
$18.96
$4.18
$19.50
$2.86B1.21.02 million shsN/A
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arvinas, Inc. stock logo
ARVN
Arvinas
0.00%+8.18%-10.29%-29.89%+2.68%
FibroGen, Inc stock logo
FGEN
FibroGen
0.00%0.00%0.00%0.00%+89.34%
Hypermarcas stock logo
HYPMY
Hypermarcas
-6.71%-5.69%-13.80%-8.63%-22.95%
MorphoSys AG stock logo
MOR
MorphoSys
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arvinas, Inc. stock logo
ARVN
Arvinas
2.46
Hold$15.42101.00% Upside
FibroGen, Inc stock logo
FGEN
FibroGen
2.00
Hold$43.00340.12% Upside
Hypermarcas stock logo
HYPMY
Hypermarcas
3.00
BuyN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest MOR, FGEN, ARVN, and HYPMY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/4/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
UpgradeSell (E+)Sell (D-)
6/3/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
Reiterated RatingOverweight$18.00
5/26/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
UpgradeStrong SellHold
5/19/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
DowngradeSell (D-)Sell (E+)
5/13/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
Boost Price TargetOverweight$18.00 ➝ $20.00
5/13/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
Boost Price TargetBuy$16.00 ➝ $18.00
5/4/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
Boost Price TargetBuy$21.00 ➝ $24.00
4/29/2026
Hypermarcas stock logo
HYPMY
Hypermarcas
UpgradeHold
4/27/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
DowngradeHoldStrong Sell
4/10/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
Reiterated RatingSell (D-)
3/19/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
Boost Price TargetBuy$18.00 ➝ $21.00
(Data available from 6/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arvinas, Inc. stock logo
ARVN
Arvinas
$262.60M1.88N/AN/A$6.76 per share1.13
FibroGen, Inc stock logo
FGEN
FibroGen
$29.62M1.34N/AN/A($50.89) per share-0.19
Hypermarcas stock logo
HYPMY
Hypermarcas
$1.38B1.95$0.45 per share8.40$3.54 per share1.08
MorphoSys AG stock logo
MOR
MorphoSys
$238.28M11.99N/AN/A$0.35 per share54.17
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arvinas, Inc. stock logo
ARVN
Arvinas
-$80.80M-$3.32N/AN/AN/A-247.54%-44.38%-28.38%8/5/2026 (Estimated)
FibroGen, Inc stock logo
FGEN
FibroGen
-$47.58M$53.480.18N/AN/A2,598.55%N/A-26.27%N/A
Hypermarcas stock logo
HYPMY
Hypermarcas
$213.10M$0.487.945.60N/A19.41%14.08%6.91%8/5/2026 (Estimated)
MorphoSys AG stock logo
MOR
MorphoSys
-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/A

Latest MOR, FGEN, ARVN, and HYPMY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/11/2026Q1 2026
Arvinas, Inc. stock logo
ARVN
Arvinas
-$0.95-$0.90+$0.05-$0.90$16.61 million$15.60 million
4/29/2026Q1 2026
Hypermarcas stock logo
HYPMY
Hypermarcas
N/A$0.10N/A$0.10N/A$383.13 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Arvinas, Inc. stock logo
ARVN
Arvinas
N/AN/AN/AN/AN/A
FibroGen, Inc stock logo
FGEN
FibroGen
N/AN/AN/AN/AN/A
Hypermarcas stock logo
HYPMY
Hypermarcas
$0.133.41%N/A27.08%N/A
MorphoSys AG stock logo
MOR
MorphoSys
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arvinas, Inc. stock logo
ARVN
Arvinas
N/A
5.44
5.44
FibroGen, Inc stock logo
FGEN
FibroGen
N/A
3.71
3.60
Hypermarcas stock logo
HYPMY
Hypermarcas
0.61
1.27
0.84
MorphoSys AG stock logo
MOR
MorphoSys
4.98
1.38
1.38

Institutional Ownership

CompanyInstitutional Ownership
Arvinas, Inc. stock logo
ARVN
Arvinas
95.19%
FibroGen, Inc stock logo
FGEN
FibroGen
72.71%
Hypermarcas stock logo
HYPMY
Hypermarcas
N/A
MorphoSys AG stock logo
MOR
MorphoSys
18.38%

Insider Ownership

CompanyInsider Ownership
Arvinas, Inc. stock logo
ARVN
Arvinas
7.30%
FibroGen, Inc stock logo
FGEN
FibroGen
3.07%
Hypermarcas stock logo
HYPMY
Hypermarcas
N/A
MorphoSys AG stock logo
MOR
MorphoSys
0.05%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arvinas, Inc. stock logo
ARVN
Arvinas
42064.52 million59.81 millionOptionable
FibroGen, Inc stock logo
FGEN
FibroGen
5704.05 million3.92 millionOptionable
Hypermarcas stock logo
HYPMY
Hypermarcas
10,481704.01 millionN/ANot Optionable
MorphoSys AG stock logo
MOR
MorphoSys
730150.62 million150.55 millionNot Optionable

Recent News About These Companies

Morphosys AG : MOR
Patent case unblocks antibody businesses
Novartis Drug Ianalumab Succeeds in Second Indication
MorphoSys takeover delivers phase 3 win for Novartis
Novartis to shut MorphSys sites amid pelabresib delay
Novartis sheds MorphoSys staff, sites after pelabresib delay
Novartis shutters MorphoSys sites, lays off staff

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Arvinas stock logo

Arvinas NASDAQ:ARVN

$7.67 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$7.73 +0.06 (+0.77%)
As of 06/18/2026 05:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

FibroGen stock logo

FibroGen NASDAQ:FGEN

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Hypermarcas stock logo

Hypermarcas OTCMKTS:HYPMY

$3.81 0.00 (0.00%)
As of 06/18/2026 03:58 PM Eastern

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, balance, Flavonid, histamin, NeoFresh, neolefrin, Neochemistry Vitamins, Neosorum, and Torsilax brand names; and consumer health products under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.

MorphoSys stock logo

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)
As of 06/18/2026

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.